Table 1.
Selected studies with CRS and HIPEC in patients with peritoneal carcinomatosis of different origin.
| Author, year | n | Tumor entity | Cytostatic agent(s) | Morbidity | Mortality | Median survival | Overall survival |
Survival CCR-0/1 |
| [%] | [%] | [months] | [%] | [%] | ||||
| Verwaal, 2003[25,41] | 105 | CRC | MMC | 35 | 8 | 22 | 28 (3-y) | 45 (5-y) |
| Glehen, 2004[33] | 506 | CRC | MMC/LOHP | 23 | 4 | 19 | 39 (3-y) | 47 (3-y) |
| Shen, 2004[34] | 77 | CRC | MMC | 30 | 12 | 16 | 25 (3-y) | 44 (3-y) |
| Glehen, 2004[29] | 49 | GC | MMC | 27 | 4 | 10 | 8 (5-y) | 29 (5-y) |
| Hall, 2004[45] | 34 | GC | MMC | 35 | 0 | 11 | - | 21 (5-y) |
| Yonemura, 2005[30] | 105 | GC | MMC/DDP | 22 | 3 | 19 | 7 (5-y) | 27 (5-y) |
| Feldmann, 2003[35] | 49 | DMPM | DDP | 25 | 0 | 92 | 59 (5-y) | - |
| Deraco, 2006[36] | 49 | DMPM | DDP/DXR DDP/MMC |
27 | 0 | - | 57 (5-y) | - |
| Yan, 2007[27] | 70 | DMPM | DDP/DXR | 36 | 3 | 59 | 49 (5-y) | - |
| Piso, 2004[37] | 19 | OC | DDP; MITO | 28 | 5 | 33 | 15 (5-y) | 44 (5-y) |
| Cotte, 2007[38] | 81 | OC | DDP | 14 | 3 | 28 | - | - |
| Di Giorgio, 2008[26] | 47 | OC | DDP | 21 | 4 | 30 | 17 (5-y) | 26 (5-y) |
CRC: colorectal cancer, GC: gastric cancer, PMP: pseudomyxoma peritonei, OC: ovarian cancer, DMPM: diffuse malignant peritoneal mesothelioma, MMC: mitomycin C, DDP: cisplatin, LOHP: oxaliplatin, DXR: doxorubicin, MITO: mitoxantrone